Journal ArticleOPEN ACCESS

Panobinostat and Multiple Myeloma in 2018

  • Yee A
  • Raje N
The Oncologist (2018) 23(5) 516-517
DOI: 10.1634/theoncologist.2017-0644
58Citations
Citations of this article
73Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

FDA and EMA approval of panobinostat offers an additional therapeutic option for multiple myeloma; however, adoption of panobinostat has been limited by its adverse event profile. Trials are ongoing to optimize the dosing of panobinostat and to identify its best partners, in order to fully realize the potential of this drug class.

Cite

CITATION STYLE

APA

Yee, A. J., & Raje, N. S. (2018). Panobinostat and Multiple Myeloma in 2018. The Oncologist, 23(5), 516–517. https://doi.org/10.1634/theoncologist.2017-0644

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free